Pilot, Non-masked, Randomized Clinical Trial for Evaluation of Stroke Rate in Patients With Blunt Cerebrovascular Injury (BCVI) Treated With Oral Acetylsalicylic Acid (ASA) 81 mg Versus ASA 325 mg (BASA).
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
The goal of this clinical trial is to compare difference between Aspirin 81 mg and Aspirin 325 mg in preventing strokes in patients with head and neck vessels injury. The main questions it aims to answer are: * If Aspirin 81 mg efficacy in prevention of stroke in patients with head and neck vessels injury is not lower than and Aspirin 325 mg. * If rate of hemorrhagic complications in patients with head and neck vessels injury taking Aspirin 81 mg is not higher than patients that take Aspirin 325 mg.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age ≥18
• All patients with blunt cerebrovascular injury are diagnosed by computed tomography angiography (CTA) upon admission
Locations
United States
California
Loma Linda University Medical Center
RECRUITING
Loma Linda
Contact Information
Primary
Maryam B Tabrizi, M.D
MTabrizi@llu.edu
(909) 558-4286
Backup
Sina Asaadi, M.D
sasaadi@llu.edu
(412) 539-7088
Time Frame
Start Date: 2023-08-23
Estimated Completion Date: 2026-12
Participants
Target number of participants: 98
Treatments
Active_comparator: Oral Daily Aspirin 81 mg
Active_comparator: Oral Daily Aspirin 325 mg
Related Therapeutic Areas
Sponsors
Leads: Loma Linda University